

Kenneth L Marek

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4405464/kenneth-l-marek-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

127
papers

12,213
citations

49
h-index

110
g-index

133
ext. papers

15,459
ext. citations

8.6
avg, IF

5.71
L-index

#	Paper	IF	Citations
127	MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 1591-601	7	2371
126	Levodopa and the progression of Parkinson's disease. <i>New England Journal of Medicine</i> , 2004 , 351, 2498-508	59.2	1355
125	The Parkinson Progression Marker Initiative (PPMI). <i>Progress in Neurobiology</i> , 2011 , 95, 629-35	10.9	793
124	MDS research criteria for prodromal Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 1600-11	7	645
123	Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. <i>New England Journal of Medicine</i> , 1992 , 327, 1541-8	59.2	500
122	Looking backward to move forward: early detection of neurodegenerative disorders. <i>Science</i> , 2003 , 302, 830-4	33.3	303
121	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. <i>Movement Disorders</i> , 2014 , 29, 454-62	7	290
120	Association of cerebrospinal fluid A β 1-42, T-tau, P-tau181, and Synuclein levels with clinical features of drug-naive patients with early Parkinson disease. <i>JAMA Neurology</i> , 2013 , 70, 1277-87	17.2	252
119	Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. <i>Archives of Neurology</i> , 2008 , 65, 716-23		251
118	The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. <i>Lancet Neurology</i> , 2008 , 7, 417-24	24.1	195
117	Role of DAT-SPECT in the diagnostic work up of parkinsonism. <i>Movement Disorders</i> , 2007 , 22, 1229-38	7	180
116	[(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. <i>Movement Disorders</i> , 2001 , 16, 1023-32	7	147
115	The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 1460-1477	5.3	142
114	Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. <i>Lancet Neurology</i> , 2015 , 14, 1002-9	24.1	141
113	Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. <i>Lancet Neurology</i> , 2013 , 12, 747-55	24.1	139
112	CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. <i>Acta Neuropathologica</i> , 2016 , 131, 935-49	14.3	138
111	Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial. <i>JAMA Neurology</i> , 2015 , 72, 1324-33	17.2	134

110	Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study. <i>Movement Disorders</i> , 2012 , 27, 406-12	7	131
109	Clinical correlates of raphe serotonergic dysfunction in early Parkinson [®] disease. <i>Brain</i> , 2015 , 138, 2964-72		127
108	(123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. <i>Archives of Neurology</i> , 2004 , 61, 1224-9		127
107	Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study. <i>Neurology</i> , 2014 , 83, 1739-46	6.5	113
106	Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT. <i>Movement Disorders</i> , 1999 , 14, 436-42	7	112
105	Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. <i>Neurology</i> , 2014 , 82, 1791-7	6.5	108
104	Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson [®] disease patients. <i>Movement Disorders</i> , 2004 , 19, 916-23	7	97
103	Defining at-risk populations for Parkinson [®] disease: lessons from ongoing studies. <i>Movement Disorders</i> , 2012 , 27, 656-65	7	96
102	Dopamine transporter imaging is associated with long-term outcomes in Parkinson [®] disease. <i>Movement Disorders</i> , 2012 , 27, 1392-7	7	94
101	Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer [®] Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. <i>Journal of Alzheimer's Disease</i> , 2018 , 61, 435-457	4.3	91
100	Plasma apolipoprotein A1 as a biomarker for Parkinson disease. <i>Annals of Neurology</i> , 2013 , 74, 119-27	9.4	90
99	How stable are Parkinson [®] disease subtypes in de novo patients: Analysis of the PPMI cohort?. <i>Parkinsonism and Related Disorders</i> , 2016 , 28, 62-7	3.6	89
98	Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort. <i>JAMA Neurology</i> , 2017 , 74, 933-940	17.2	86
97	Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. <i>Neurology</i> , 2017 , 89, 1959-1969	6.5	84
96	The natural history of the syndrome of primary progressive freezing gait. <i>Archives of Neurology</i> , 2002 , 59, 1778-83		84
95	Estimating the half-lives of PCB congeners in former capacitor workers measured over a 28-year interval. <i>Journal of Exposure Science and Environmental Epidemiology</i> , 2011 , 21, 234-46	6.7	82
94	Longitudinal Change of Clinical and Biological Measures in Early Parkinson [®] Disease: Parkinson [®] Progression Markers Initiative Cohort. <i>Movement Disorders</i> , 2018 , 33, 771-782	7	73
93	Finding useful biomarkers for Parkinson [®] disease. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	69

92	Can we image premotor Parkinson disease?. <i>Neurology</i> , 2009 , 72, S21-6	6.5	68
91	Movement disorder society criteria for clinically established early Parkinson [®] disease. <i>Movement Disorders</i> , 2018 , 33, 1643-1646	7	67
90	Cognition in individuals at risk for Parkinson [®] : Parkinson associated risk syndrome (PARS) study findings. <i>Movement Disorders</i> , 2016 , 31, 86-94	7	66
89	The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease. <i>JAMA Neurology</i> , 2014 , 71, 1520-8	17.2	63
88	Tau PET imaging with F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 911-919	8.9	63
87	The new definition and diagnostic criteria of Parkinson [®] disease. <i>Lancet Neurology</i> , 2016 , 15, 546-8	24.1	61
86	The Effect of the COVID-19 Pandemic on People with Parkinson [®] Disease. <i>Journal of Parkinsons Disease</i> , 2020 , 10, 1365-1377	5.3	56
85	Age dependence of brain β amyloid deposition in Down syndrome: An [18F]florbetaben PET study. <i>Neurology</i> , 2015 , 84, 500-7	6.5	55
84	Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging. <i>Neurology</i> , 2016 , 86, 748-54	6.5	54
83	Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. <i>JAMA Neurology</i> , 2020 , 77, 1408-1419	17.2	54
82	Correlates of excessive daytime sleepiness in de novo Parkinson [®] disease: A case control study. <i>Movement Disorders</i> , 2015 , 30, 1371-81	7	53
81	[F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer [®] disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 2077-2089	8.8	50
80	Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes. <i>Brain</i> , 2019 , 142, 3565-3579	11.2	50
79	Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson [®] disease: the PPMI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 78-88	5.5	49
78	In vivo assessment and dosimetry of 2 novel PDE10A PET radiotracers in humans: 18F-MNI-659 and 18F-MNI-654. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 1297-304	8.9	49
77	Longitudinal analyses of cerebrospinal fluid β synuclein in prodromal and early Parkinson [®] disease. <i>Movement Disorders</i> , 2019 , 34, 1354-1364	7	48
76	Kinetic Modeling of the Tau PET Tracer F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 1124-1131	8.9	47
75	Association between β synuclein blood transcripts and early, neuroimaging-supported Parkinson [®] disease. <i>Brain</i> , 2015 , 138, 2659-71	11.2	47

74	Longitudinal assessment of excessive daytime sleepiness in early Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 653-662	5.5	45
73	A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. <i>Movement Disorders</i> , 2009 , 24, 2081-90	7	44
72	Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson's disease patients. <i>Journal of Nuclear Medicine</i> , 2007 , 48, 857-64	8.9	44
71	Risk factors for Parkinson's disease and impaired olfaction in relatives of patients with Parkinson's disease. <i>Movement Disorders</i> , 2007 , 22, 2249-55	7	42
70	Occupational exposure to PCBs reduces striatal dopamine transporter densities only in women: a beta-CIT imaging study. <i>Neurobiology of Disease</i> , 2010 , 38, 219-25	7.5	41
69	Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits. <i>Movement Disorders</i> , 2015 , 30, 1885-92	7	40
68	Ergot alkaloids: interaction with presynaptic dopamine receptors in the neostriatum and olfactory tubercles. <i>European Journal of Pharmacology</i> , 1980 , 62, 137-46	5.3	39
67	Characterization in humans of 18F-MNI-444, a PET radiotracer for brain adenosine 2A receptors. <i>Journal of Nuclear Medicine</i> , 2015 , 56, 586-91	8.9	38
66	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. <i>Lancet Neurology</i> , 2020 , 19, 71-80	24.1	37
65	Tissue-specific regulation of peptidyl-glycine alpha-amidating monooxygenase expression. <i>Endocrinology</i> , 1989 , 125, 2279-88	4.8	36
64	Concordance for Parkinson's disease in twins: A 20-year update. <i>Annals of Neurology</i> , 2019 , 85, 600-605	9.4	35
63	Abolishing the 1-year rule: How much evidence will be enough?. <i>Movement Disorders</i> , 2016 , 31, 1623-1627		35
62	Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease. <i>Journal of Neuroinflammation</i> , 2017 , 14, 164	10.1	34
61	Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 937-943	8.9	34
60	Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study. <i>Movement Disorders</i> , 2010 , 25, 1627-32	7	34
59	Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers. <i>Molecular Imaging and Biology</i> , 2019 , 21, 509-518	3.8	33
58	Biosynthesis, development, and regulation of neuropeptide Y in superior cervical ganglion culture. <i>Journal of Neurochemistry</i> , 1989 , 52, 1807-16	6	32
57	Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. <i>Movement Disorders</i> , 2020 , 35, 1999-2008	7	32

56	The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies. <i>Movement Disorders</i> , 2017 , 32, 726-738	7	31
55	Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments. <i>Movement Disorders</i> , 2013 , 28, 1980-6	7	31
54	Serum urate and probability of dopaminergic deficit in early "Parkinson's disease". <i>Movement Disorders</i> , 2011 , 26, 1864-8	7	31
53	Cognition and the course of prodromal Parkinson's disease. <i>Movement Disorders</i> , 2017 , 32, 1640-1645	7	29
52	Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis. <i>Clinical and Translational Science</i> , 2018 , 11, 63-70	4.9	28
51	Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2016 , 3, 346-55	5.3	26
50	Striatal dopamine transporters correlate with simple reaction time in elderly subjects. <i>Neurobiology of Aging</i> , 2008 , 29, 1237-46	5.6	25
49	Imaging the dopamine system to assess disease-modifying drugs: studies comparing dopamine agonists and levodopa. <i>Neurology</i> , 2003 , 61, S43-8	6.5	25
48	Early-phase [F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 2911-2922	8.8	24
47	Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies. <i>Annals of Neurology</i> , 2003 , 53 Suppl 3, S160-6; discussion S166-9	9.4	24
46	Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression. <i>Annals of Neurology</i> , 2008 , 64 Suppl 2, S111-21	9.4	23
45	Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials. <i>Alzheimers and Dementia</i> , 2017 , 13, 1117-1124	1.2	22
44	Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson's Disease. <i>Journal of Parkinsons Disease</i> , 2015 , 5, 581-94	5.3	22
43	Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 71-5	1.7	22
42	Neuroimaging over the course of Parkinson's disease: from early detection of the at-risk patient to improving pharmacotherapy of later-stage disease. <i>Seminars in Nuclear Medicine</i> , 2012 , 42, 406-14	5.4	21
41	Hemi-parkinsonism due to a midbrain arteriovenous malformation: dopamine transporter imaging. <i>Movement Disorders</i> , 2001 , 16, 350-3	7	21
40	Preclinical properties and human in vivo assessment of 123I-ABC577 as a novel SPECT agent for imaging amyloid- β . <i>Brain</i> , 2016 , 139, 193-203	11.2	19
39	Psychiatric status after human fetal mesencephalic tissue transplantation in Parkinson's disease. <i>Biological Psychiatry</i> , 1995 , 38, 498-505	7.9	19

38	Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson Disease Participants in the Parkinson Progression Markers Initiative: A Cross-Sectional Study. <i>Movement Disorders</i> , 2020 , 35, 833-844	7	18
37	Evaluation of Dosimetry, Quantitative Methods, and Test-Retest Variability of F-PI-2620 PET for the Assessment of Tau Deposits in the Human Brain. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 920-927	8.9	17
36	Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers. <i>Movement Disorders</i> , 2016 , 31, 906-14	7	17
35	Evolution of Alzheimer Disease Cerebrospinal Fluid Biomarkers in Early Parkinson Disease. <i>Annals of Neurology</i> , 2020 , 88, 574-587	9.4	16
34	The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson Disease. <i>Journal of Parkinsons Disease</i> , 2019 , 9, 553-563	5.3	16
33	Predictors of time to requiring dopaminergic treatment in 2 Parkinson disease cohorts. <i>Movement Disorders</i> , 2011 , 26, 608-13	7	16
32	Individual-reader diagnostic performance and between-reader agreement in assessment of subjects with Parkinsonian syndrome or dementia using 123I-ioflupane injection (DaTscan) imaging. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 1288-96	8.9	14
31	Clinical utility of DaTscan imaging in the evaluation of patients with parkinsonism: a US perspective. <i>Expert Review of Neurotherapeutics</i> , 2017 , 17, 219-225	4.3	14
30	Novel recruitment strategy to enrich for LRRK2 mutation carriers. <i>Molecular Genetics & Genomic Medicine</i> , 2015 , 3, 404-12	2.3	14
29	Kinetic modeling, test-retest, and dosimetry of 123I-MNI-420 in humans. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 1760-7	8.9	14
28	Neuroimaging trials of Parkinson disease progression. <i>Journal of Neurology</i> , 2004 , 251 Suppl 7, vii9-13	5.5	14
27	Neural transplantation for neurodegenerative diseases: past, present, and future. <i>Annals of the New York Academy of Sciences</i> , 1993 , 695, 258-66	6.5	14
26	Plasma Bsynuclein and cognitive impairment in the Parkinson Associated Risk Syndrome: A pilot study. <i>Neurobiology of Disease</i> , 2018 , 116, 53-59	7.5	13
25	Predictors of time to initiation of symptomatic therapy in early Parkinson disease. <i>Annals of Clinical and Translational Neurology</i> , 2016 , 3, 482-94	5.3	13
24	Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson Disease. <i>Clinical and Translational Science</i> , 2019 , 12, 240-246	4.9	12
23	Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study. <i>Movement Disorders</i> , 2017 , 32, 1636-1640	7.4	12
22	A practical approach to remote longitudinal follow-up of Parkinson disease: the FOUND study. <i>Movement Disorders</i> , 2014 , 29, 743-9	7	11
21	Comparison of an Online-Only Parkinson Disease Research Cohort to Cohorts Assessed In Person. <i>Journal of Parkinsons Disease</i> , 2020 , 10, 677-691	5.3	10

20	Longitudinal Measurements of Glucocerebrosidase activity in Parkinson [®] patients. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 1816-1830	5.3	10
19	Feasibility and safety of lumbar puncture in the Parkinson [®] disease research participants: Parkinson [®] Progression Marker Initiative (PPMI). <i>Parkinsonism and Related Disorders</i> , 2019 , 62, 201-209	3.6	9
18	Traditional neuropsychological correlates and reliability of the automated neuropsychological assessment metrics-4 battery for Parkinson [®] disease. <i>Parkinsonism and Related Disorders</i> , 2012 , 18, 864-870	3.6	9
17	Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson [®] Disease Research: The Fox Insight Cohort Experience. <i>Journal of Parkinsons Disease</i> , 2020 , 10, 665-675	5.3	9
16	Predicting Progression in Parkinson [®] Disease Using Baseline and 1-Year Change Measures. <i>Journal of Parkinsons Disease</i> , 2019 , 9, 665-679	5.3	8
15	Development of a Disease Progression Model for Leucine-Rich Repeat Kinase 2 in Parkinson [®] Disease to Inform Clinical Trial Designs. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 553-562	6.1	8
14	Coalition Against Major Diseases: Precompetitive Collaborations and Regulatory Paths to Accelerating Drug Development for Neurodegenerative Diseases. <i>Therapeutic Innovation and Regulatory Science</i> , 2013 , 47, 632-638	1.2	7
13	Clinical and Imaging Progression in the PARS Cohort: Long-Term Follow-up. <i>Movement Disorders</i> , 2020 , 35, 1550-1557	7	7
12	123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T β-synuclein Parkinson [®] disease cohort versus Parkinson [®] disease. <i>Movement Disorders</i> , 2018 , 33, 1734-1739	7	7
11	Molecular PET imaging in multicenter Alzheimer [®] therapeutic trials: current trends and implementation strategies. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 1783-93	4.3	6
10	Dopamine transporter imaging predicts clinically-defined β-synucleinopathy in REM sleep behavior disorder. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 201-212	5.3	6
9	The role of the core imaging laboratory in multicenter trials. <i>Seminars in Nuclear Medicine</i> , 2010 , 40, 338-344	4.6	5
8	A Bayesian mathematical model of motor and cognitive outcomes in Parkinson [®] disease. <i>PLoS ONE</i> , 2017 , 12, e0178982	3.7	5
7	Impact of disclosure of individual imaging results in a multi-center Parkinson clinical trial. <i>Journal of Parkinsons Disease</i> , 2014 , 4, 629-38	5.3	2
6	Differential regulation of neuropeptide Y and catecholamine production in superior cervical ganglion cultures. <i>Molecular and Cellular Neurosciences</i> , 1990 , 1, 262-9	4.8	2
5	Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson [®] Disease. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 53-58	2.2	1
4	Observations on a 2-Step Approach to Screening for Parkinson Disease-Reply. <i>JAMA Neurology</i> , 2017 , 74, 1506-1507	17.2	
3	Reply: Unusual DAT scan results. <i>Movement Disorders</i> , 2013 , 28, 847	7	

- 2 Imaging of Dopamine Transporters: Biomarker for Progression in Parkinson's Disease. *CNS Neuroscience & Therapeutics*, **2006**, 5, 19-19
- 1 Prospects for Slowing the Progression of Parkinson's Disease **2005**, 141-iii